



Program

9th Annual Meeting - Strasbourg, France

Continuing Education Courses

Tuesday, September 15

Please note that participation in the Continuing Education course requires attendees to register for the courses. Please visit the Registration Desk if you wish to sign up for a CE Course on-site.

Morning Courses: CE(1), CE(2), CE(3), CE(4)

Morning Courses include a continental breakfast and refreshments during the break. (For AM sessions only.)

8:00 Courses in Session

12:00 Courses Concludes

Each CE Course Book has a detailed agenda.

Afternoon Courses: CE(5), CE(6), CE(7), CE(8)

Afternoon Courses include a box lunch that can be picked up in the respective meeting room at 12:30 and refreshments during the break. Afternoon Course Schedule (may vary depending on course).

14:00 Courses in Session

18:00 Courses Concludes

Each CE Course Book has a detailed agenda.

18:30 Welcoming Reception—EVERYONE INVITED!!!!

19:30 All SPS Hosted Functions Adjourn

Scientific Sessions and Other Events

Wednesday, September 16

9:00 **Welcome and Announcements**
Rick Briscoe, PhD, President of the Safety Pharmacology Society
Auditorium Schweitzer

9:15 **Keynote Address: Risk Assessment, Perception and Communication**
Speaker: Ragnar Löfstedt, PhD, King's College, London, United Kingdom
Auditorium Schweitzer

10:30 **Break**
Exhibit Area

11:00 **Chronobiology and the Implications for Safety Assessment**
Session Co-Chair and Tract Leader: Brian Guth, PhD and Co-Chair Maxim Solevieff, MD, PhD
Speaker: Björn Lemmer, Dr. med., Dr. h.c., Management Board EMEA; Institute of Pharmacology and Toxicology, Ruprecht-Karls University, Heidelberg, Germany
Auditorium Schweitzer

12:00 **Lunch Break (Exhibit Area) Stand-up Buffet Provided**

Visit Vendors and Poster Viewing

12:30–13:15 Posters 9–25 (except 21) attended by presenter

13:15–14:00 Posters 26–42 (except 32, 36) attended by presenter

13:00–14:00 Jr./Student Scientists Posters 1–8, 21, 32, 36, 50–52, 59, 84, 86, 89, 90–92, and 150 attended for judging

14:00

A. Translational: The Animal Model Framework

Session Chair: Paul C. Harrison, PhD

Schuman

Session presentations will focus on the predictive value of preclinical CNS models to observed effects or adverse events associated with drugs which have progressed into the clinic.

Using the Animal Model Framework to Explore Translation of Safety Pharmacology Cardiovascular Data to Phase I Clinical Trials

Speaker: Rob Wallis, PhD, Pfizer Inc., United Kingdom

Can the Animal Model Framework be Applied to Non-Cardiovascular Safety Pharmacology Models?

Speaker: Lorna Ewart, PhD, AstraZeneca, United Kingdom

B. Emerging Technologies

Session Co-Chairs: Mike Hawk, PhD and Anthony Bahinski, PhD

Tivoli 2

This session will highlight the emerging trends within safety testing to investigate direct (drug related) and in-direct (non drug related) effects upon the cardiovascular system.

